A neutral, harm-reduction guide to pemvidutide, an investigational GLP-1/glucagon agonist noted for lean-mass sparing and MASH data.
At a glance
Best for
Pemvidutide is an investigational peptide with balanced, roughly 1:1 glucagon and GLP-1 dual receptor agonist activity, developed by Altimmune. The GLP-1 arm suppresses appetite and drives weight loss, while the glucagon arm acts directly on the liver to cut liver fat, inflammation, and fibrosis. It is notable in its class for lean-mass sparing: in the MOMENTUM Phase 2 obesity trial, body composition analysis attributed about 78 percent of weight lost to fat and 22 percent to lean mass, and its IMPACT Phase 2b program showed significant MASH resolution.
Pemvidutide is investigational and not approved; a Phase 3 MASH trial (PERFORMA) was planned for 2026. This is an educational tracking guide, not medical advice or a recommendation.
In the trials, pemvidutide is titrated upward over weeks to a maintenance dose to limit GI effects, given once weekly by subcutaneous injection. Doses referenced anywhere are trial context only, not a recommendation.
The lean-mass sparing story is a trial-level average, not a guarantee for any individual, so muscle tracking still matters. Weight and liver benefits build over months. Protein and resistance training remain worthwhile even with a lean-sparing agent.
Pemvidutide is investigational and not approved. Its full safety profile is still being defined, and glucagon agonism adds metabolic and heart-rate considerations on top of GLP-1 class GI effects. Any non-trial access is outside the evidence base; use only with medical supervision.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.